Evidence map›Paper›PMID 38572952›Full record

ArticleCancer medicine2024

Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.

Shuji Murakami, Kanako Shinada, Yuka Otsutsumi, Fumiko Komine, Yuan Yuan, Junko Nakamura, Seigo Katakura, Tetsuro Kondo, Terufumi Kato, Tomoyuki Yokose and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shuji MurakamiDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.ORCID 0000-0001-5104-5493
Kanako ShinadaDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Yuka OtsutsumiDepartment of Pathology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Fumiko KomineRiken Genesis Co., Ltd., Shinagawa-ku, Tokyo, Japan.
Yuan YuanRiken Genesis Co., Ltd., Shinagawa-ku, Tokyo, Japan.
Junko NakamuraRiken Genesis Co., Ltd., Shinagawa-ku, Tokyo, Japan.
Seigo KatakuraDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Tetsuro KondoDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Terufumi KatoDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Tomoyuki YokoseDepartment of Pathology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Haruhiro SaitoDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Kanagawa Prefectural Hospital Organization · JPGenesis Research Institute · JP

Funding

Riken Genesis Co., Ltd.
6 · The paper itself

Abstract

purposeGenetic mutation detection has become an important step in nonsmall-cell lung cancer (NSCLC) treatment because of the increasing number of drugs that target genomic rearrangements. A multiplex test that can detect multiple gene mutations prior to treatment is thus necessary. Currently, either next-generation sequencing (NGS)-based or polymerase chain reaction (PCR)-based tests are used. We evaluated the performance of the Oncomine Dx Target Test (ODxTT), an NGS-based multiplex biomarker panel test, and the AmoyDx Pan Lung Cancer PCR Panel (AmoyDx PLC panel), a real-time PCR-based multiplex biomarker panel test. MATERIALS AND

methodsPatients with histologically diagnosed NSCLC and a sufficient sample volume to simultaneously perform the AmoyDx PLC panel and ODxTT-M were included in the study. The success and detection rates of both tests were evaluated.

resultsBiopsies revealed 116 cases of malignancies, 100 of which were NSCLC. Of these, 59 met the inclusion criteria and were eligible for analysis. The success rates were 100% and 98% for AmoyDx PLC panel and ODxTT-M, respectively. Nine driver mutations were detected in 35.9% and 37.3% of AmoyDx PLC and ODxTT-M panels, respectively. EGFR mutations were detected in 14% and 12% of samples using the AmoyDx PLC panel and ODxTT-M, respectively. Of the 58 cases in which both NGS and AmoyDx PLC panels were successful, discordant results were observed in seven cases. These differences were mainly due to different sensitivities of the detection methods used and the gene variants targeted in each test. DISCUSSION: The AmoyDx PLC panel, a PCR-based multiplex diagnostic test, exhibits a high success rate. The frequency of the nine genes targeted for treatment detected by the AmoyDx PLC panel was comparable to the frequency of mutations detected by ODxTT-M. Clinicians should understand and use the AmoyDx PLC panel and ODxTT-M with respect to their respective performances and limitations.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkersHigh-Throughput Nucleotide SequencingHumansMultiplex Polymerase Chain ReactionMutationBiomarkersAmoyDx pan lung cancer PCR panelnonsmall‐cell lung cancerOncomine Dx Target Test

Identifiers

PMID38572952
PMCPMC10993699
OpenAlexW4393934208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.